Biopôle
VC Fund
Epalinges, Switzerland
Biopôle is a clinical work and research firm.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 91%
Last updated:
For AI agents: llms.txt
Industries Biopôle invests in
Stages Biopôle invests in
Countries Biopôle invests in
Round sizes
Round size
- Seed
- $112k–$112k
- Grant
- $65k–$99k
Investment Focus
Industry
- Health Care 4 (36%)
- Therapeutics 3 (27%)
- Biotechnology 3 (27%)
- Medical Device 3 (27%)
- Medical 2 (18%)
Stage
- Grant 5 (45%)
- Seed 3 (27%)
- Debt Financing 1 (9%)
- Corporate Round 1 (9%)
Country
- Switzerland 9 (82%)
- France 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Neuria is an interdisciplinary team at the interface between neuroscience, psychology, and computer science, which develops interventions to improve or restore your health | $308.1K / Debt Financing / Aug 19, 2026 | ||
| Emovo Care SA is an ISO 13485 certified medical device company developing accessible robotic devices to bring movement home for people with motor impairments. The first product is an active orthosis that enables hemiparetic stroke patients to move their hands at home and will be CE marked by 2022. The core technology behind the device was developedduring a PhD at EPFL, where the research received worldwide media attention for its novel brain-computer interfaces. | $111.6K / Seed / Nov 06, 2025 | ||
| Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to end the threat of antimicrobial resistance through an AI-powered technology. | $111.6K / Seed / Nov 06, 2025 | ||
| Novostia is a privately held medical device company incorporated in 2017 in Microcity Neuchâtel, Switzerland, developing an innovative artificial heart valve, designed for patients of any age, including children. | $6.6M / Corporate Round / Sep 09, 2024 | ||
| Precision oncology includes new ways of treating cancer such as targeted therapies and immunotherapies. These approaches are more specific and effective than current treatments. In the near future, they will considerably reduce worldwide cancer burden. As of today, only a fraction of the 18 million yearly diagnosed patients benefit from precisiononcology. To increase the number of beneficiaries, new diagnostic tools are needed to match the specific needs of precision oncology to define patients' eligibility and monitor treatment response. | $98.6K / Grant / Oct 05, 2023 | ||
| Limula provides a unique platform technology enabling scale out of cell therapy production. By bringing manufacturing closer to the patients, our solution will broaden access to these highly personalised treatments. Our patented solution is composed of an automation unit and single use kits, allowing healthcare providers to safely manufacture CGTin a decentralized manner. We support companies at all stages of the cell therapy life cycle, from R&D to routine production. | $98.6K / Grant / Oct 05, 2023 | ||
| Voltiris develops solar modules for greenhouses. The company uses spectral filtering technology to allow essential light for plant growth to pass through while converting unused light into renewable energy. This dual-use approach enables greenhouse owners to generate electricity without compromising crop yield, promoting sustainability and energyindependence. | $98.6K / Grant / Oct 05, 2023 | ||
| Perivision combines artificial intelligence, virtual reality, and the cloud to build the next generation of systems to understand visual function. The company's systems improve workflow efficiency in practices and hospitals and provide deeper clinical insight into eye diseases. | Seed / Jul 18, 2023 | ||
| Volumina is active in the field of tissue engineering and develops injectable 3D scaffolds for the reconstruction of volumes of soft tissues (fat, muscles, glandular tissues, supporting and connective tissues) that have been lost after tumor ablation, disease, trauma, or for purely esthetically purposes. | $90K / Grant / Feb 03, 2023 | ||
| Limula provides a unique platform technology enabling scale out of cell therapy production. By bringing manufacturing closer to the patients, our solution will broaden access to these highly personalised treatments. Our patented solution is composed of an automation unit and single use kits, allowing healthcare providers to safely manufacture CGTin a decentralized manner. We support companies at all stages of the cell therapy life cycle, from R&D to routine production. | $65.1K / Grant / Oct 11, 2022 | ||
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Biopôle invest in?
Biopôle invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Grant and Seed stage. Most of the 11 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Biopôle's check size?
Biopôle typically joins rounds of $112k–$112k at Seed and $65k–$99k at Grant. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Biopôle participates in.
When did Biopôle last invest?
The most recent investment recorded for Biopôle closed in Aug 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
